PM Portfolio Manager Reports

From Portfolio Manager reports

Security report / GH

GH Operating Console

Guardant Health is a high-growth precision-oncology diagnostics platform with a demanding proof window. The filed lane shows strong Q1 revenue and volume momentum, but the equity case still depends on Shield reimbursement quality, oncology growth, commercial-spend leverage, free-cash-flow improvement, and the 2027 convertible-note path.

Metadata Knowledge Lane Fallback Chart
Ticker GH
Knowledge reviewed 2026-07-04
Links checked 2026-07-05
Chart source Local API
Module 01 / Price

Selected-Security Chart

API required

Loading GH daily chart from the local report API.

Loading GH chart...

Module 02 / Proof window

Current Company View

Execution test
Next read Q2 results need to show Shield and oncology volume on plan while cash burn and commercial intensity improve.
Measured base

Q1 2026 revenue was $301.7M, up 48%; oncology revenue was $205.0M, and screening revenue was $41.6M.

Main proof issue

Growth is not yet self-funding: Q1 free cash flow was $(71.2)M and 2026 FCF burn guidance remains $(185)M-$(195)M.

Valuation context

The lane frames GH as premium and execution-sensitive after a May 2026 close near $115 and low-double-digit EV/FY2026 revenue.

Next evidence

Q2 2026 earnings, Shield volume versus 230k-245k guidance, payer/ASP quality, oncology growth, FCF burn, and convertibles.

Q1 revenue $301.7M Up 48% year over year
Oncology $205.0M About 86k tests; volume up 47%
Screening $41.6M About 44k Shield tests
Gross margin 65% / 66% GAAP / non-GAAP in Q1
Free cash flow $(71.2)M Q1 2026 company-disclosed FCF
Cash / converts $1.2B / $1.50B March 31, 2026 snapshot
Exposure Map

Business Profile, Segments, And Exposure

Guardant converts oncology workflows, colorectal screening, payer policy, and biopharma demand into lab-testing and data revenue.

Business model

Diagnostics platform

Clinical oncology testing remains the revenue anchor, biopharma/data extends the platform into companion diagnostics and studies, and Shield is the high-expectation screening leg.

Disclosure map

Revenue detail, limited unit economics

Revenue by category is visible, but segment profitability and Shield-specific unit economics are not disclosed. That keeps margin-model confidence bounded.

Oncology

Largest and still accelerating base.

Q1 oncology revenue was $205.0M with about 86,000 tests and 47% volume growth.

More useful evidence

Q2 oncology volume, reimbursement, and Guardant360 Liquid CDx pricing or ADLT progress.

Shield screening

Fastest-growing swing factor.

Q1 screening revenue was $41.6M with about 44,000 Shield tests, and 2026 Shield guidance was raised.

More useful evidence

Payer coverage, ASPs, collections, guideline language, and CAC efficiency.

Biopharma and data

Platform breadth, uneven cadence.

Q1 biopharma/data revenue was $53.0M, up 17%, tied to studies, companion diagnostics, and data services.

More useful evidence

Study revenue, pharma R&D demand, and data-service conversion.

Licensing and other

Small and not central.

FY2025 licensing and other revenue was $8.6M after nonrecurring milestone revenue in the prior year.

More useful evidence

Any material milestone or licensing contribution that changes the mix.

Value Drivers

Relative Value And Drivers

The report read is premium and execution-sensitive: revenue growth is strong, but conversion and per-share quality decide durability.

Revenue Shield adoption
Blood-based screening is the largest forward swing factor.

FDA approval, Medicare coverage qualification, NCCN inclusion, and rising Shield volume support the ramp, but the economics depend on coverage and collection quality.

Confirm with Shield tests, screening revenue, ASPs, payer updates, and guideline language.
Revenue Oncology platform
Oncology scale is the current anchor.

Guardant360 Liquid/CDx, Smart Platform migration, and rising oncology volume support the established engine if reimbursement and ASPs remain intact.

Confirm with oncology volume, product mix, payer behavior, and therapy-selection evidence.
Margin Commercial spend
Gross margin is not the same as operating leverage.

Q1 gross margin was strong, but sales and marketing grew sharply as Shield and oncology infrastructure scaled.

Confirm with sales and marketing as a percentage of revenue and gross-profit dollar conversion.
Per share Convertibles and SBC
The balance sheet buys time but does not remove dilution risk.

Large cash and securities support investment, while convertibles and SBC keep per-share value creation on the proof list.

Confirm with the 2027 note path, share count, settlement choices, and SBC trends.
Guidance

Guidance Path And Tests

Revenue guidance improved after Q1 volume strength. Cash-flow guidance still says the model has not proven self-funding.

Question
Can GH hold the raised 2026 revenue plan?

Confirm if Q2 supports the $1.30B-$1.32B revenue guide and oncology remains near the updated growth path.

Warn if the Q2 guide implies slower oncology, weaker screening revenue, or a narrower growth base.

Question
Is Shield volume high-quality growth?

Confirm if Shield tracks 230k-245k 2026 tests with healthy payer coverage, ASPs, and collections.

Warn if volume grows only through heavy acquisition cost or weak reimbursement quality.

Question
Does cash burn narrow as guided?

Confirm if FCF burn stays inside the $(185)M-$(195)M full-year guide and commercial expense scales better.

Warn if gross-profit dollars are consumed by sales, marketing, R&D, or working-capital outflow.

Operating Evidence

KPIs And Catalysts

The next catalyst window is Q2 2026 earnings and guidance, expected around August 2026 in the filed lane.

Total revenue growth
$301.7M in Q1, up 48%.

This confirms the high-growth setup that supports the premium platform read.

Oncology revenue and tests
$205.0M and about 86,000 tests.

Oncology remains the largest revenue and data-scale engine.

Shield screening
$41.6M and about 44,000 Shield tests.

Shield is the fastest-moving swing factor in the forward narrative.

Gross margin
About 65% GAAP and 66% non-GAAP.

Test economics can improve with scale, but commercial spending decides operating leverage.

Free cash flow
$(71.2)M in Q1 2026.

The path from growth to self-funding remains the central valuation risk.

Commercial spend
Sales and marketing rose 62% year over year.

Spend efficiency is the operating-leverage bridge to watch in Q2 and the second half.

Capital

Financial Quality And Capital Allocation

Liquidity supports the growth plan, but negative cash flow and convertibles keep the equity-quality test open.

Liquidity and cash burn

Runway is not the problem yet.

Guardant reported about $1.2B of cash, restricted cash, and marketable securities at March 31, 2026, but Q1 operating cash flow and free cash flow were both negative.

Capital allocation remains growth-first: clinical evidence, commercial infrastructure, R&D, and platform expansion take priority over cash returns.

Convertible and per-share path

The 2027 note path matters.

Convertible senior notes had $1.503B of carrying value at March 31, 2026, including a material 2027 maturity path.

Stock-based compensation and settlement choices should be measured against per-share value creation, not only revenue growth.

Position

Competitive Position

Guardant has a credible oncology liquid-biopsy edge. Shield has a convenience wedge but still carries clinical-positioning constraints.

Proven so far

Oncology scale

Oncology revenue and test volume continue to accelerate, supporting the liquid-biopsy platform claim.

Product breadth

The platform spans therapy selection, monitoring, screening, and biopharma/data services.

Market recognition

External coverage and price action show investors have rewarded reimbursement, FDA, and growth milestones.

Not proven yet

Shield substitution

Advanced-adenoma sensitivity limits claims that Shield can fully replace colonoscopy or stool-based modalities.

Commercial leverage

The sales engine is still costly to scale, so gross margin has not translated into positive free cash flow.

Segment economics

Revenue mix is visible, but segment profit and Shield unit economics remain undisclosed.

Street View

Ownership, Flows, Valuation, And Tape

The tape has rewarded execution, but that same rerating raises the tolerance problem if Q2 or reimbursement evidence disappoints.

Tape

Event-sensitive and supportive

The lane cites sharp moves after earnings, Guardant360 Liquid CDx approval, and healthcare growth rotation. That supports investor demand but raises the execution bar.

Latest exact July 3 market data was not retrieved in the filed source run.
Valuation

Premium platform multiple

Using the May 20 close and latest share count, the lane estimates a mid-teens-billion-dollar equity value and low-double-digit EV/FY2026 revenue.

Peer valuation was qualitative rather than a point-in-time comp table.
Flows

Hard flow data missing

Ownership concentration, passive flow, beta, volatility, and short interest were not retrieved in the lane. The visible per-share issue is convertibles and SBC.

Official analyst coverage route
Scenarios

Scenario Assessment

Scenarios center on whether volume growth becomes higher-quality revenue and narrower cash burn.

Base High growth continues while burn narrows

Oncology and Shield stay on plan, 2026 guidance holds, and gross-profit growth begins to narrow cash burn without a step-change in dilution pressure.

Upside Shield and oncology exceed expectations

Shield reaches or exceeds the top end of volume guidance, oncology remains above plan, payer coverage broadens, and pricing or volume improves.

Downside Reimbursement or guideline friction hits Shield

Shield adoption slows, ASPs or payer coverage disappoint, or clinical-performance debate limits physician or guideline positioning.

Downside Funding pressure overwhelms revenue growth

Commercial spend or R&D keeps rising faster than gross profit, FCF burn misses guidance, and convertibles or SBC become a larger per-share drag.

Triggers

Monitoring Trigger Board

These are evidence checks from the filed lane, not chart levels or price triggers.

Q2 results

Confirm beat-and-guide durability.

Confirm if Q2 revenue, oncology volume, Shield volume, and full-year guidance remain at or above the raised path.

Warn if any growth leg slows without a temporary explanation.

Shield economics

Track coverage, volume, ASP, and collections.

Confirm if Shield tracks 230k-245k tests with supportive payer and guideline signals.

Warn if volume depends on weak reimbursement or heavy acquisition cost.

Operating leverage

Watch spend versus gross-profit dollars.

Confirm if sales and marketing as a percentage of revenue improves while gross-profit dollars grow.

Warn if FCF burn exceeds the full-year guidance range.

Capital structure

Watch 2027 note treatment and SBC.

Confirm if settlement, refinancing, and share count remain manageable.

Warn if financing terms or SBC pressure per-share value before self-funding is proven.

Risks

Risks, Invalidations, And Quality Flags

The highest-severity risks sit in reimbursement, commercial efficiency, clinical positioning, and capital structure.

High Reimbursement and adoption
Basis

Shield and oncology economics depend on payer coverage, ASPs, collections, and guideline language.

Warning

Coverage friction or weaker collections would hit the highest-expectation growth leg.

Reduce concern

Broader payer coverage and stable ASPs while volume tracks guidance.

High Commercial efficiency
Basis

Commercial scaling may consume gross-profit improvement if Shield requires sustained heavy sales investment.

Warning

Sales and marketing keeps rising faster than revenue or gross profit.

Reduce concern

FCF burn narrows within guide and spend ratios improve.

High Clinical positioning
Basis

Shield's blood-draw convenience is real, but advanced-adenoma sensitivity limits substitution claims.

Warning

Physicians, payers, or guidelines frame Shield too narrowly for the volume assumptions.

Reduce concern

Adherence-expanding positioning supports durable reimbursed use.

Medium Capital structure
Basis

Convertibles and SBC can dilute per-share outcomes before sustained cash generation is proven.

Warning

2027 settlement, refinancing, or share count creates more dilution or cash use than expected.

Reduce concern

Cash burn narrows enough to preserve financing flexibility.

Diagnostics

Freshness And Known Unknowns

The lane is current to the July 4 source occurrence and the page links were checked on July 5, 2026.

Source freshness

Latest filed view: July 4, 2026.
Source run

GH profile and research were generated from the requested July 4 source occurrence.

Web check

Guardant IR, Q1 release, Q1 filing, presentation, filings, analyst coverage, and governance routes were checked July 5, 2026.

Market data

Live price and market cap resolve only through the local report API chart module.

Known gaps

Use these as next diligence routes.
Transcripts

Full recent earnings-call transcripts were not retrieved in the source pass.

Proxy and flows

Latest DEF 14A detail, hard ownership, short interest, beta, volatility, and peer valuation were not normalized.

Unit economics

Segment profitability and Shield-specific unit economics remain undisclosed.

Reports Home Securities Daily Report Weekly Report